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Abstract Noonan syndrome is a relatively common mul-
tiple malformation syndrome with characteristic facies,
short stature and congenital heart disease, most commonly
pulmonary stenosis (Noonan, Clin Pediatr, 33:548–555,
1994). Recently, a mutation in the PTPN11 gene (Tartaglia,
Mehler, Goldberg, Zampino, Brunner, Kremer et al., Nat
Genet, 29:465–468, 2001) was found to be present in about
50% of individuals with Noonan syndrome. The pheno-
type noted in Noonan syndrome is also found in a number
of other syndromes which include LEOPARD (Gorlin,
Anderson, Blaw, Am J Dis Child, 17:652–662, 1969), Cardio-
facio-cutaneous syndrome (Reynolds, Neri, Hermann,
Blumberg, Coldwell, Miles et al., Am J Med Genet,
28:413–427, 1986) and Costello syndrome (Hennekam,
Am J Med Genet, 117C(1):42–48, 2003). All three of these
syndromes share similar cardiac defects and all have
postnatal short stature. Very recently, HRAS mutations
(Aoki, Niihori, Kawame, Kurosawa, Ohashi, Tanaka et al.,
Nat Genet, 37:1038–1040, 2005) have been found in the
Costello syndrome and germline mutations in KRAS and
BRAF genes (Rodriguez-Viciana, Tetsu, Tidyman, Estep,
Conger, Santa Cruz et al., Nat Genet, 2006; Niihori, Aoki,
Narumi, Neri, Cave, Verloes et al., Nat Genet, 38:294–296,
2006) in the Cardio-facio-cutaneous syndrome. Phenotypic
overlap between these genetic disorders can now be ex-
plained since each is caused by germline mutations that are
major components of the RAS-MAPK pathway. This path-
way plays an important role in growth factor and cytokine





Noonan Syndrome (NS) has been recognized for about
40 years [1] but the genetic cause was not found until 2003
when mutations in the PTPN11 gene were reported [2].
Shortly afterwards LEOPARD syndrome (LS), a rare alleic
variant of NS was found to have specific mutations in the
PTPN11 gene [25]. Cardio-facio-cutaneous (CFC) syn-
drome and Costello syndrome (CS), both rare syndromes,
share significant phenotypic overlap with NS especially in
infancy. The common features of facial dysmorphism, short
stature and similar cardiac findings in all four conditions
suggest a similar underlying pathogenesis. In 2005 [6],
mutations in the HRAS oncogene were found to be the
cause of CS and in 2006 mutations in KRAS, BRAF, MEK1
and MEK2 genes [7, 8] were identified in CFC. All of these
germline mutations are components of the RAS-MAPK
pathway which plays an important role in growth factors
and cytokine signaling. In this review, the clinical findings
of the four syndromes will be reviewed. NS will be
discussed in more detail since it is common and more
clinical studies are available.
1.1 Noonan syndrome
NS is one of the more common non-chromosomal
syndromes seen in children with congenital heart disease
with an estimated incidence of 1 in 1,500 [1]. Although
there is wide phenotypic variation in NS, distinctive facial
features include hypertelorism, down-slanting palpebral
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ears, malar hypoplasia, ptosis and often a short neck. The
phenotype changes significantly with time. In the newborn,
there is excessive nuchal skin which is the result of prenatal
cystic hygroma. During infancy, the head is relatively large,
the eyes are often prominent and round, there is a high
nasal bridge which may be flat, and the neck appears short.
At 3 to 4 years of age, the body becomes more stocky and
the chest more prominent. The chest deformities often
become significant. In later childhood, the facial appear-
ance begins to show coarse features and becomes more
triangular as the chin lengthens. The eyes become less
prominent and the ptosis may be more apparent. In the
teenager and young adult, as the neck lengthens webbing
may become more apparent, the facial features are more
triangular and become sharper, the nose has a pinched root
and a thin high bridge. An older adult has prominent nasal
labial folds, a high anterior hairline and the skin often
appears rather transparent and wrinkled.
In most, the prenatal history is unremarkable but
polyhydramnios is frequent. Height and weight are within
normal limits at birth but height begins to drop off within a
few months and over 70% of patients with NS have
significantly short stature. Some patients with NS have
significant feeding difficulties with resulting failure-to-
thrive and require tube feedings. Although this may
contribute to the poor gain in weight, short stature occurs
equally in children who have no feeding problems in
infancy. Other important findings include a chest deformity
which may be in the form of a pectus carinatum or pectus
excavatum, apparent widely spaced nipples and a relatively
broad chest. Scoliosis and kyphosis occur in about 15% of
patients. Muscle hypotonia is frequent and may account for
some of the motor delay. Significant mental retardation is
uncommon but some degree of learning disability is
frequent and may require special help in school. Eye
findings, especially strabismus and refractive errors are
common and an occasional patient will have a coloboma.
All children with NS should have a complete eye
examination. Since conductive hearing loss is rather
frequent, children should have a hearing evaluation. Over
half of the males with NS have either one or both testes
undescended and delay in puberty is common for both
males and females.
Easy bruising is common in NS and a variety of bleeding
problems have been reported [9]. These include deficiency
of Factor XI, Von Willebrand’s disease, thrombocytopenia
and platelet function defects. In addition, low levels of
Factor VIII and XII have also been noted. Hepatospleno-
megaly, usually unexplained, is present in about 25% of
patients particularly in infancy. Lymphatic abnormalities
occur in less than 20% of patients but may present serious
problems. Over 80% of patients with NS have a cardiac
finding. Pulmonary stenosis is, by far, the most common
but nearly every cardiac lesion has been reported. In
addition, hypertrophic cardiomyopathy may occur.
It was recognized early on that NS could be transmitted
in an autosomal dominant manner. In 1994, Jamieson et al
[10] was able to map the gene for NS to the distal part of
chromosome 12q. Not all families with NS studied showed
this linkage suggesting that more than one gene was likely
to be involved in the etiology. In 2002, Tartaglia [2] found a
mutation in the PTPN11 gene to be present in about 50% of
patients with NS. This gene regulates the production of a
protein called SHP-2 which is essential in several intracel-
lular signal transduction pathways and controls a number of
developmental processes including cardiac semilunar val-
vulogenesis. The protein is expressed throughout the body
and it is an important player in cellular response to growth
factors, hormones, cytokines and cell adhesion molecules.
The PTPN11 mutations in NS are clustered in interacting
portions of the N-SH2 in PTTP domains. This mutation
results in a gain of function for SHP-2.
Children with NS often present to the endocrinologists
because of the short stature, delayed puberty or undescend-
ed testes in males. Although height and weight are usually
in the normal range at birth, height drops off within the first
few months. In general, there is at least a 2-year delay
between bone age and chronological age. Continued growth
may occur until the early 20s. In both males and females,
there is a delay in puberty. Females seem to possess normal
fertility. Males, as expected due to undescended testes,
appear to have decreased fertility but male transmission is
well described and not uncommon.
The cause of short stature in NS is really not clear. After
pharmacological stimuli, growth hormone secretion was
usually normal in patients studied but a small number
showed a subnormal response. Others have shown a
neurosecretory growth hormone dysfunction to be present
in some patients but this did not appear to have any effect
on the response to growth hormone [11]. There have been
previous studies looking at the IgF-1 levels which have
been below normal for the majority reported. A consider-
able number of children have undergone treatment with
human biosynthetic growth hormone. The majority of
studies have shown similar results. There is a significant
increase in growth velocity in the first and second year of
growth hormone treatment [12–16]. The velocity in growth
tends to diminish in succeeding years. Several authors
claim that the predicted adult height has been increased in
patients treated with growth hormone but there have been
no real controlled studies to document the long-term effect
of growth hormone on adult height. In those studies where
bone age as well as actual height were measured, the
increase in bone age was equal or slightly greater than the
overall increase in height. If the bone age acceleration
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growth hormone therapy could actually decrease the adult
height. Since there was little data available regarding adult
height in NS, we recently [17] published a study of 73
adults who were all over 21 years of age at the time of their
last measurement. Thirty-one percent of males and 32% of
females achieved an adult height that was at the tenth
percentile or greater which would be considered within a
normal range. The remainder all fell below the tenth
percentile but importantly 38% of males and 54.5% of
females had an adult height below the third percentile. Adult
height was unrelated to the presence or severity of cardiac
disease and none of the adults achieving a normal height had
been treated with growth hormone. Dr. Municchi et al [16]
suggests that long-term serial height measurement over
years comparing treated and untreated patients is needed to
clearly show the benefit of growth hormone therapy on
final adult height. There is no question that adult height can
be achieved at an earlier age with the use of growth
hormone.
With the discovery of the PTPN11 mutation, it is now
possible to study patients with NS positive for a mutation
and compare them with NS patients who do not carry a
mutation of the PTPN11 gene. The large cohort reported by
Ranke [18] suggested that weight and length were normal
in 119 newborns with NS. With the availability of genetic
testing, several recent studies have shown that mean birth
length for NS patients with a mutation is slightly below
normal and is less than that of the non-mutated NS
newborns [19, 20]. In a study by Zenker [20], 88% of
PTPN11 positive mutated children older than 3 years of age
had a height less than two standard deviations and were
significantly shorter than non-mutated children. All recent
studies [21] suggest that there is a more severe mechanism
acting on growth retardation in NS patients carrying a
PTPN11 mutation. A recent study from France [19]
evaluated 35 patients with NS, 20 of whom had a PTPN11
mutation. There was a trend to a shorter birth length in
mutated versus non-mutated newborns and small for
gestational age tended to be more frequent in mutated
versus non-mutated patients. By 6 years of age, patients
with mutations were significantly shorter than patients
without mutations. The results of hormonal studies showed
a normal growth hormone secretion after pharmacological
stimuli and a low serum IgF-1 and ALS concentrations
which is in contrast with a normal IgFBP-3 level. Since the
PTPN11 gene has a negative effect on intracellular
signaling downstream from several growth factor receptors,
a growth hormone post receptor signaling resistance could
represent the mechanism of stunted growth in NS. They felt
that the lower growth response to growth hormone
treatment observed in mutated versus non-mutated patients
suggests some degree of resistance to growth hormone.
Another recent study by Binder et al [22] showed a similar
pattern. Data from these two studies would be in favor of
growth hormone resistance by a late post receptor signaling
defect specific for IgF-1 and ALS that does not effect
IgFBP-3 stimulation. Changes in height during the first
2 years of growth hormone therapy in the pre-pubertal
group show catch-up growth was less pronounced in
patients with a mutation compared to those without a
mutation. Fortunately, in all the studies using growth
hormone, no adverse results have been observed. Many
patients have undergone serial echocardiograms and none
have shown an increase in their left ventricular mass index
during growth hormone treatment [23]. These recent studies
suggesting that there may be a primary IgF-1 deficiency in
NS has stimulated and been incorporated into a phase II
clinical study which will investigate the use of IPLEXtm
(mecasermin rinfabate) (rDNA origin) which will be given
by injection to treat growth failure due to insulin-like
growth factor IgF-1 deficiency. Although we still do not
understand how the mutation in the PTPN11 gene affects
SHP-2, the result apparently is a disruption in the growth
hormone IgF-1 axis and IgF-1 deficiency which could be
the cause of growth failure.
1.2 LEOPARD syndrome (LS)
Gorlin [3], in 1969, introduced the acronym LEOPARD
(LS) to describe a rare syndrome that shares many features
similar to NS. These include autosomal dominant inheri-
tance, similar facial dysmorphism and similar cardiac
defects with an overabundance of hypertrophic cardiomy-
opathy compared to pulmonary stenosis. The characteristic
cutaneous finding of lentigines is the main distinguishing
characteristic. In addition, unilateral or bilateral hearing loss
is frequent.
Sarkozy et al [24, 25] recently reported clinical and
molecular studies in a consecutive study of 30 patients with
LS and found mutations in the PTPN11 gene in 27 of the 30
patients studied. Mutations in LS have all occurred in exons
7, 12 and 13 while the more typical NS have the great
majority of mutations occur in exons 3, 8 and 13. It is of
interest that the mutations in patients with LS show a loss
of function rather than gain a function as is found in the
more typical NS patients.
Zenker [20] noted a specific mutation T468M in exon 12
which was also reported by Sarkozy in seven of their pa-
tients with LS to have less adverse effects on body growth.
Only two of the ten patients with the T468M mutation have
short stature.
A cardiac abnormality was present in 71% of the patients
with LS, with 80% of those showing hypertrophic cardio-
myopathy. Pulmonary stenosis was present in two patients
and a partial AV canal in another.
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It is often difficult to distinguish an infant with CFC from NS
although, with time, the phenotype becomes more distinc-
tive.PatientswithCFC[4] have a high forehead, a relatively
large head and bitemporal constriction. Like NS, they have
a downward slant of the palpebral fissures, posteriorly
rotated ears and a flat nasal bridge. The hair is usually
sparse, curly and friable and absent eyebrows are frequent.
The skin changes are variable but include keratosis pilaris
with patchy hyperkeratosis [26]. In time, the phenotype for
CFC becomes more distinctive and less Noonan-like. These
patients are significantly delayed in both motor and mental
skills and, like NS, they are hypotonic, often have failure-
to-thrive with frequent gastrointestinal complaints and often
require tube feedings. Cardiovascular abnormalities are
similar to NS although hypertrophic cardiomyopathy is
more common than in the typical NS patient. Although
these children appear to be of normal height and weight at
birth, they soon fail-to-thrive and short stature is found in
78% [27]. Bone age is significantly delayed and osteopenia
is occasionally observed.
Very recently, mutations in four separate genes have
been found to be associated with CFC [3, 4]. These four
genes include BRAF, KRAS, MEK1 and MEK2. All of these
genes belong to the same RAS-ERK pathway that regulates
cell differentiation, proliferation and apoptosis. It is likely
that the mechanism causing short stature in NS may be
similar to that causing short stature in CFC. This is a very
rare disease and there is little information regarding
endocrine studies in patients with CFC.
1.4 Costello syndrome
Costello Syndrome (CS) [28] is a rare condition with a
distinctive facial appearance which may be difficult to
distinguish from NS and CFC in infancy. Although height
and weight are normal or above normal at birth, severe
growth retardation is the rule postnatally. Like NS, they
have a large head, short wide nose and short neck. Unlike
NS or CFC, these patients usually have thick and relatively
prominent lips and tongue. They also have loose skin on the
hands and feet and deep palmar and plantar creases. There is
significant mental and motor delay. Cardiovascular abnor-
malities are found in about 60% and they are remarkably
similar to that found in NS and CFC. Pulmonary stenosis,
atrial septal defect and hypertrophic cardiomyopathy are the
most common lesions [29]. Of particular interest is the high
incidence of cardiac arrhythmias noted particularly in
infancy [30] that is not characteristic of either CFC or NS.
Recently Aoki et al [4] reported mutations in HRAS a
proto-oncogene to cause CS. Gripp et al [31] confirmed this
finding and reported 33 of 40 patients with a clinical
diagnosis of CS to have a HRAS mutation. All the
mutations were de novo. Patients with CS are at a
significantly increased risk for the development of malig-
nancy, particularly rhabdomyosarcoma, neuroblastoma,
ganglioneuroblastoma, and transitional cell carcinoma of
the bladder. Although few studies of growth hormone have
been carried out in Costello patients, the findings are very
similar to that of NS. Response to growth hormone
treatment has been variable. Kerr et al [32] have suggested
that in CS, hormone treatment may be harmful because of
the propensity to tumor formation and the presence of
hypertrophic cardiomyopathy. He described two patients,
one who had mild left ventricular hypertrophy with normal
function before growth hormone was started. After 3 months
of treatment, the cardiomyopathy progressed with signifi-
cant left ventricular outflow tract obstruction with a
gradient of 60 mmHg. He was treated with Propranolol.
There was no further progression of the cardiomyopathy in
spite of continuation of growth hormone. In the second
case, growth hormone was started at 12 months and
continued until age 26 months when a large pelvic mass
was discovered which was proven to be an embryonal
rhabdomyosarcoma. Growth hormone was stopped after the
tumor was recognized. In spite of extensive chemotherapy,
the patient died. Since CS is associated with both subaortic
hypertrophic cardiomyopathy and tumors, the role of
growth hormone in these two patients is unknown. At the
present time, it is unclear whether growth hormone is
beneficial or harmful in CS.
2 Conclusion
NS,LS,CFCandCSallhavesignificantphenotypicoverlap.
Although they may be difficult to distinguish early on in life,
in time they can usually be distinguished clinically. Recent
studies show that each of these syndromes is caused by a
germline mutation in a key component of the highly
conserved RAS, RAF-ERK-MAP kinase cascade which is
better known for its roles in growth factor and cytokines
signaling in cancer pathogenesis. We still do not understand
howthese specific mutationscausethediseaseand whythere
are such distinct phenotypic differences in mutations within
the same signaling pathway. Tartaglia et al [33] recently
provided evidence that specificity in amino acid substitu-
tion is relevant to the functional deregulation of SHP-2 and
disease pathogenesis. They showed NS mutations have less
potency for promoting SHP-2 gain of function than do
leukemia-associated mutations and that Y279C and T468M
amino acid substitutions noted in LS engender a loss of
SHP-2 catalytic activity. It is not surprising that a mutation
in the HRAS gene associated with CS has an increased
incidence of tumors since these mutations are identical to
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syndrome has not been associated with malignancy but the
number of reported cases is still quite small with long-term
follow-up limited. For the endocrinologist, it is interesting
that all of the syndromes have a high incidence of short
stature. LS, on the other hand, with loss of function appears
to have a lower incidence of short stature but the higher
incidence of hypertrophic cardiomyopathy. It will be of
interest to see how effective IPLEXtm will be in treating the
growth failure in NS and perhaps these related syndromes as
well. Since the growth failure starts very soon after birth and
may indeed start before birth, it is certainly possible that
treatment may be necessary very early in life to achieve
anywhere near a normal growth stature.
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